Reuben A. Guttman
Guttman

Title: Director

Phone: (202) 386-9500

E-mail: rguttman@gelaw.com

Education:

Emory University School of Law, J.D. (1985)

University of Rochester, B.A. (1981)

Admissions:

District of Columbia, Georgia, New Jersey, Pennsylvania, U.S. Court of Appeals for the DC Circuit, U.S. Court of Appeals for the 3rd Circuit, U.S. Court of Appeals for the 4th Circuit, U.S. Court of Appeals for the 11th Circuit, U.S. District Court for the DC, U.S. District Court for the MD, U.S. District Court for NE, U.S. District Court for NJ, U.S. District Court for the Northern District of GA, U.S. District Court for the Eastern District of PA, U.S. District Court for the Western District of MI

Biography

Reuben Guttman is a director at Grant & Eisenhofer, where he heads the firm's Washington, D.C. office. His practice involves complex litigation and class actions. He has represented clients in claims brought under the Federal False Claims Act, securities laws, the Price Anderson Act, Department of Energy (DOE) statutes and regulations, the Worker Adjustment and Retraining Notification Act (WARN), Racketeer Influenced and Corrupt Organizations Act (RICO) and various employment discrimination, labor and environmental statutes. He has also tried and/or litigated claims involving fraud, breach of fiduciary duty, antitrust, business interference and other common law torts.

The International Business Times has called Mr. Guttman "one of the world's most prominent whistleblower attorneys." He has served as counsel in some of the largest recoveries under the False Claims Act. In 2013, Mr. Guttman was lead counsel in an intervened case by the United States Department of Justice against Pfizer, Inc. involving the kidney-transplant drug Rapamune. On July 30, 2013, The U.S. Department of Justice announced that Pfizer had agreed to pay $491 million to settle criminal and civil charges stemming from the illegal marketing of Rapamune by Wyeth Pharmaceuticals, which was acquired by Pfizer in 2009. Mr. Guttman represented two whistleblowers - sales representative Marlene Sandler and pharmacist Scott Paris - who brought the initial action in the case, United States ex rel. Sandler et al. v. Wyeth Pharmaceuticals, Inc. Also in 2013, Mr. Guttman was lead counsel in U.S. ex rel. Kurnik v. Amgen, Inc. et al., resulting in the recovery of $24.9 million from Amgen. That case exposed kickbacks designed to increase sales of the drug Aranesp.

In 2012, he served as lead counsel for the lead whistleblower, Meredith McCoyd, in U.S. ex rel. McCoyd v. Abbott Labs, which resulted in a $1.6 billion recovery for the government. In 2012, he also represented one of the whistleblowers in a case against GlaxoSmithKline that returned over $3 billion to the government. Also in 2012, Mr. Guttman represented whistleblower Lynn Szymoniak whose qui tam case, involving fraudulent mortgage assignments, was resolved as part of the government's $25 billion settlement with some of the world's largest banks. He represented one of the six main whistleblowers in litigation resulting in the government's September 2009 $2.3 billion settlement with Pfizer Pharmaceutical, and he served as counsel in U.S. ex rel. Johnson v. Shell Oil Co., 33 F. Supp. 2d 528 (E.D. Tex. 1999), where over $300 million was recovered from the oil industry. On behalf of a European whistleblower, Mr. Guttman was counsel in litigation that resulted in a $13 million settlement.

Mr. Guttman served as lead counsel in a series of cases resulting in the recovery of more than $30 million under the Federal Fair Labor Standards Act. Cases brought by Mr. Guttman on behalf of nuclear weapons workers at "Manhattan Project" nuclear weapons sites resulted in congressional oversight and changes in procurement practices, and dread disease compensation legislation, affecting the nation's nuclear weapons complex and its workforce. In addition, he served as lead counsel in litigation brought on behalf of prison workers in the District of Columbia, which resulted in injunctive relief protecting workers against exposure to blood-borne pathogens. Mr. Guttman served as lead counsel in a mediation before the United States Equal Employment Opportunity Commission, resulting in work place standards and back pay for minority employees at a large Texas oil refinery.

Mr. Guttman is the author and/or editor of numerous articles, book chapters, and technical publications, and his commentary has appeared in Market Watch, American Lawyer Media, AOL Government, Accounting Today, and the Jerusalem Post. His article, "Pharmaceutical Regulation in the United States: A Confluence of Influences," was published in Chinese by the Peking University Public Interest Law Journal, Vol. 1, Page 187 (2010). He is co-author of Gonzalez v. Hewitt, SEC v. HG Pharmaceutical, and U.S. ex Rel. Rodriguez v. Hughes, which are case files published by the Emory University School of Law Center for Advocacy and Dispute Resolution (2010) used to train law students and practicing attorneys.

Among his publications, Mr. Guttman is author or co-author of Chapters 5-10 in Internal Investigations: How to Protect Your Clients or Companies in the Global, Post Dodd-Frank World (Practising Law Institute, 2012). He has appeared on ABC Nightly News, CNN, Bloomberg News, and has been quoted in major publications, including The Wall Street Journal, The New York Times, The Washington Post, The Los Angeles Times, The Atlanta Journal-Constitution, USA Today, Houston Chronicle, Dallas Morning News and national wire services, including the Associated Press, Reuters and Bloomberg. Mr. Guttman's commentary on politics and the law has appeared in the European Lawyer, and he writes a regular blog for its affiliated website, The Global Legal Post - www.globallegalpost.com.

In addition to his writings, Mr. Guttman has testified before committees of the United States House of Representatives and the United States Senate on the Asbestos Hazard Emergency Response Act (AHERA). In 1992, he advised President-elect Clinton's transition team on labor policy and worker health and safety regulation.

Mr. Guttman earned his law degree at Emory University School of Law graduating in 1985, and his bachelor's degree from the University of Rochester in 1981. He is a Senior Fellow and Adjunct Professor at the Emory University School of Law Center for Advocacy and Dispute Resolution and has been a Team Leader for Emory Law School's Kessler-Eidson Trial Techniques Program. Mr. Guttman is currently serving a three year term on the Dean's Advisory Board of Emory Law School. As part of a U.S. State Department program in conjunction with the Center for Advocacy and Dispute Resolution, he has been one of five visiting professors at Universidad Panamericana in Mexico City training Mexican judges and practitioners on oral advocacy and trial practice. He is a contributing editor of a soon-to-be published text book on trial practice for Mexican practitioners. For the fall semester, 2012, Mr. Guttman was appointed as an Adjunct Professor at the Rutgers University Law School, where he taught in the trial program.

Mr. Guttman is a member of the Board of Directors of the American Constitution Society. He is also the Chairman of the American Association for Justice Qui Tam Litigation Group. He is a founder of and advisor to a new online journal at Emory Law School entitled Emory Corporate Governance and Accountability Review (ECGAR), and a faculty member of the National Institute of Trial Advocacy. He has been a guest lecturer at a number of universities, including Jiao Tong University in Shanghai, Peking University in Beijing and Renmin University in Beijing. In 2006, he was invited by the Dutch Embassy in China to share his knowledge with experts in China about changes to the nation's labor laws. He is the founder of www.whistleblowerlaws.com and www.thecorporateinsider.com, and co-founder of www.voicesforcorporateresponsibility.com.